Correlations of plasma proprotein convertase subtilisin/kexin type 9 level with different types of acute cerebral infarction and nature of carotid atherosclerotic plaque

XU Yijun; TAO Chunhua; WANG Xingyi; ZHANG Song; LIU Zhensheng; WANG Yingge

doi:10.7619/jcmp.20220069

Journal of Clinical Medicine in Practice > 2022 > 26(11): 53-57. > DOI: 10.7619/jcmp.20220069

XU Yijun, TAO Chunhua, WANG Xingyi, ZHANG Song, LIU Zhensheng, WANG Yingge. Correlations of plasma proprotein convertase subtilisin/kexin type 9 level with different types of acute cerebral infarction and nature of carotid atherosclerotic plaque[J]. Journal of Clinical Medicine in Practice, 2022, 26(11): 53-57. DOI: 10.7619/jcmp.20220069

Citation:

PDF (742 KB)

Correlations of plasma proprotein convertase subtilisin/kexin type 9 level with different types of acute cerebral infarction and nature of carotid atherosclerotic plaque

1.
Department of Neurology, the Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, 225000
2.
Medical College of Yangzhou University, Yangzhou, Jiangsu, 225000
3.
Nursing College of Yangzhou University, Yangzhou, Jiangsu, 225000

More Information

Received Date: January 05, 2022
Available Online: May 15, 2022

Graphical Abstract

Abstract

Abstract

Objective
To investigate the correlations of plasma proprotein convertase subtilisin/kexin type 9(PCSK9) level with different types of acute cerebral infarction (ACI) and nature of carotid atherosclerotic plaque.
Methods
Patients were divided into different groups according to TOAST classification, severity of the disease and stability of plaque, and PCSK9 level in each group was compared.Logistic regression analysis was used to explore the risk factors of unstable plaque, and the receiver operating characteristic (ROC) curve was drawn to evaluate the predictive effect of PCSK9.
Results
Among the 236 enrolled subjects, 158 patients were diagnosed as ACI, and 142 of them were diagnosed with plaque.The plasma PCSK9 level in ACI patients was significantly higher than that in controls (P < 0.05);the PCSK9 level and the National Institutes of Health Stroke Scale (NIHSS) score in ACI patients with type of large atherosclerosis (LAA) were significantly higher than those in patients with other subtypes (P < 0.05);the PCSK9 level in the unstable plaque group was significantly higher than that in the stable plaque group (P < 0.05).PCSK9 was positively correlated with the degree of neurological impairment (r_s=0.468, P < 0.05).Logistic regression analysis showed that PCSK9 was the risk factor for LAA-type ACI and carotid unstable plaque (OR=1.010, 95%CI, 1.001 to 1.019, P < 0.05;OR=1.007, 95%CI, 1.001 to 1.013, P < 0.05).ROC curve indicated that when the level of PCSK9 was higher than 438.21 ng/mL, the patients had higher risk of LAA-type ACI.
Conclusion
PCSK9 may induce LAA-type cerebral infarction by inducing formation of carotid unstable plaque.

FullText(HTML)

References (21)

References

[1]	王陇德, 刘建民, 杨弋, 等. 我国脑卒中防治仍面临巨大挑战: 《中国脑卒中防治报告2018》概要[J]. 中国循环杂志, 2019, 34(2): 105-119. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH201902002.htm
[2]	LIU L S, BAI X Q, GAO Y, et al. PCSK9promotes oxLDL-induced PC12 cell apoptosis through the bcl-2/bax-caspase 9/3 signaling pathway[J]. J Alzheimer's Dis, 2017, 57(3): 723-734. doi: 10.3233/JAD-161136
[3]	QI Z Y, HU L, ZHANG J J, et al. PCSK₉ (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36[J]. Circulation, 2021, 143(1): 45-61. doi: 10.1161/CIRCULATIONAHA.120.046290
[4]	中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2014[J]. 中华神经科杂志, 2015, 48(4): 246-257. https://www.cnki.com.cn/Article/CJFDTOTAL-YXZL201606005.htm
[5]	王英歌, 陈露, 张新江, 等. 老年脑梗死患者血浆MMP-9、CD105和TIMP-1的表达水平及其与颈动脉粥样硬化斑块稳定性的相关性[J]. 中国老年学杂志, 2017, 37(12): 2912-2913. doi: 10.3969/j.issn.1005-9202.2017.12.022
[6]	ZHAO H, ZHAO X, LIU X, et al. Association of carotid atherosclerotic plaque features with acute ischemic stroke: A magnetic resonance imaging study[J]. European Journal of Radiology, Elsevier Ireland Ltd, 2013, 82(9): e465-e470.
[7]	LATIMER J, BATTY J A, NEELY R D G, et al. PCSK9 inhibitors in the prevention of cardiovascular disease[J]. JThromb Thrombolysis, 2016, 42(3): 405-419. doi: 10.1007/s11239-016-1364-1
[8]	RASHID S, TAVORI H, BROWN P E, et al. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and-independent mechanisms[J]. Circulation, 2014, 130(5): 431-441. doi: 10.1161/CIRCULATIONAHA.113.006720
[9]	TANG Z H, JIANG L, PENG J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages[J]. IntJMolMed, 2012, 30(4): 931-938.
[10]	KYSENIUS K, MUGGALLA P, MÄTLIK K, et al. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling[J]. CellMol Life Sci, 2012, 69(11): 1903-1916.
[11]	APAIJAI N, MOISESCU D M, PALEE S, et al. Pretreatment with PCSK9 inhibitor protects the brain against cardiac ischemia/reperfusion injury through a reduction of neuronal inflammation and amyloid beta aggregation[J]. JAm Heart Assoc, 2019, 8(2): e010838. doi: 10.1161/JAHA.118.010838
[12]	LI J, LIANG X, WANG Y Y, et al. Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis[J]. MolMedRep, 2017, 16(2): 1817-1825.
[13]	SHEN L, PENG H C, NEES S N, et al. Proprotein convertase subtilisin/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport[J]. FEBS Lett, 2013, 587(9): 1271-1274. doi: 10.1016/j.febslet.2013.02.027
[14]	NAVARESE E P, KOLODZIEJCZAK M, WINTER M P, et al. Association of PCSK₉ with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: the PCSK9-REACT study[J]. IntJCardiol, 2017, 227: 644-649.
[15]	CAMMISOTTO V, PASTORI D, NOCELLA C, et al. PCSK9 regulates Nox2-mediated platelet activation via CD36 receptor in patients with atrial fibrillation[J]. Antioxidants, 2020, 9(4): 1-14.
[16]	PASTORI D, NOCELLA C, FARCOMENI A, et al. Relationship of PCSK₉ and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation[J]. JAmCollCardiol, 2017, 70(12): 1455-1462.
[17]	WANG H, WANG Q, WANG J, et al. Proprotein convertasesubtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice[J]. Scientific Reports, Springer US, 2017, 7(1): 1-8. doi: 10.1038/s41598-016-0028-x
[18]	SHARMA S, MAZYA M V, WAHLGREN N, et al. IV thrombolysis in very severe and severe ischemic stroke: results from the SITS-ISTR Registry[J]. Neurology, 2016, 86(22): 2115.
[19]	ALI K, CHEEK E, SILLS S, et al. Development of a conversion factor to facilitate comparison of National Institute of Health Stroke Scale scores with Scandinavian Stroke Scale scores[J]. CerebrovascDis Basel Switz, 2007, 24(6): 509-515.
[20]	ALMONTASHIRI N A M, VILMUNDARSON R O, GHASEMZADEH N, et al. Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies[J]. Plos One, 2014, 9(9): 1-9.
[21]	CHENG J M, OEMRAWSINGH R M, GARICIA-GARICIA H M, et al. PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study[J]. Atherosclerosis, Elsevier Ltd, 2016, 248: 117-122.

[1]	TIAN Xueqin, WANG Jiahao, JI Linling, ZHAO Gege, JIANG Jing, WANG Yingge. Correlations of plasma cyclin-dependent kinase 9 level with disease progression and prognosis in patients with acute large artery atherosclerotic cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 6-12. DOI: 10.7619/jcmp.20243593
[2]	BAO Qingying, ZHANG Lingling, MA Songhua, CHEN Xiaobo, JIANG Zhi, JIANG Qiqun. Correlations between serum soluble growth stimulationgene 2 protein, brain natriuretic peptide and the degree of carotid atherosclerosis in patients with acute ischemic stroke[J]. Journal of Clinical Medicine in Practice, 2024, 28(8): 70-74, 78. DOI: 10.7619/jcmp.20240200
[3]	ZHANG Benyin, LU Wuzhang, YANG Jing. Relationships of National Institutes of Health Stroke Scale score, plasma homocysteine level with acute cerebral infarction and analysis in related risk factors[J]. Journal of Clinical Medicine in Practice, 2021, 25(22): 102-105. DOI: 10.7619/jcmp.20212001
[4]	CAO Lan, TAO Yujian, ZHAO Yuanlu, ZHANG Pan. Analysis in risk factors of solitary pulmonary nodules[J]. Journal of Clinical Medicine in Practice, 2021, 25(1): 38-40, 44. DOI: 10.7619/jcmp.20200457
[5]	YANG Li, SUN Xiaohui, HE Jing, WU Yuliang. Influence of trimetazidine combined with clopidogrelon carotid atherosclerotic plaques and inflammatory factors of patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2019, 23(11): 20-23. DOI: 10.7619/jcmp.201911006
[6]	CHENG Liqun. Correlation between leukoaraiosis and cerebral infarction and risk factors[J]. Journal of Clinical Medicine in Practice, 2018, (7): 42-44. DOI: 10.7619/jcmp.201807011
[7]	SHI Guiwen. Risk factors of type 2 diabetes mellitus complicated with carotid atherosclerosis and analysis of neutrophil to lymphocyte ratio and platelets to lymphocyte ratio levels[J]. Journal of Clinical Medicine in Practice, 2018, (1): 27-30. DOI: 10.7619/jcmp.201801009
[8]	CHU Jie, DU Ping, HE Chen, WANG Fangbing, HAO Yingping. Value of apolipoprotein B/A-1 ratio combined with carotid plaque nature examination in predicting the risk of patients with coronary heart disease[J]. Journal of Clinical Medicine in Practice, 2017, (11): 35-37. DOI: 10.7619/jcmp.201711011
[9]	ZHANG Jifang. Research on occurrence of macrosomia and its related risk factors[J]. Journal of Clinical Medicine in Practice, 2014, (3): 116-118. DOI: 10.7619/jcmp.201403041
[10]	WEI Shiyou, WANG Yanlin. Study on risk factors for relapse of stroke in young people[J]. Journal of Clinical Medicine in Practice, 2013, (17): 16-19. DOI: 10.7619/jcmp.201317005

Cited By

Cited by

Periodical cited type(7)

1.	张焕. 急性脑梗死患者凝血功能与颈动脉颅外段狭窄及斑块的关系. 吉林医学. 2025(02): 296-300 .
2.	李桂芳，张菊莲，徐小冬，张容. 急性脑梗死联合轻微脑出血患者的危险因素及对心脑血管事件发生率的影响. 中国急救复苏与灾害医学杂志. 2024(02): 187-190 .
3.	吕志坤，魏萌萌，李国珍，唐彦，卢波，黄黎明，王海虹，贾磊华. 动态动脉硬化指数联合血清肿瘤坏死因子受体相关因子6、前蛋白转化酶枯草溶菌素9对急性分水岭脑梗死病人的预后价值. 安徽医药. 2024(07): 1363-1368 .
4.	冯艳，罗文平，张明明，佘林聪，王家欣，孙涌鑫，陈昊青，张薇. 前蛋白转化酶枯草溶菌素-kexin 9型抑制剂对血管内皮的保护作用机制研究进展. 实用临床医药杂志. 2024(15): 142-148 . 本站查看
5.	陈桂林. 急性脑梗死患者颈动脉斑块危险因素分析. 医药前沿. 2024(09): 36-38 .
6.	符美茵，燕香菊，崔晓娟，郑东. 超声联合血清前蛋白转化酶枯草溶菌素9、五聚素3检测对下肢动脉硬化闭塞症患者动脉狭窄程度的评估价值. 心脑血管病防治. 2024(12): 62-65 .
7.	刘景祎，李富慧，张丽，宋彦. 血清IL-17、Sortilin及PCSK9水平与老年脑梗死患者颈动脉硬化的关系研究. 中国卫生检验杂志. 2023(18): 2241-2244 .

Other cited types(0)

Get Citation

PDF

XML

Article views (182) PDF downloads (17) Cited by(7)

Turn off MathJax

Article Contents

Abstract

References

Correlations of plasma proprotein convertase subtilisin/kexin type 9 level with different types of acute cerebral infarction and nature of carotid atherosclerotic plaque